Results of longitudinal MRD analysis in bone marrow performed at the time of (or within 6 weeks before) SCT, between SCT and study entry, and during imatinib therapy and follow-up. □ represents a negative result of quantitative RT-PCR; ▪, a positive PCR reaction; and ▦, a possible nonspecific result (ie, only 1 positive PCR reaction in duplicate samples or positivity exclusively in the nested PCR). R indicates relapse with the time from start of imatinib to relapse given in parentheses; * autologous SCT; #, patients with active GvHD; and §, SCT after dose-reduced conditioning; N.D., not done; A & W, alive and well.